TG Therapeutics | TGTX - Current Liabilities


TG Therapeutics reported $156.81M in Current Liabilities for its fiscal quarter ending in September of 2025.





Current Liabilities Change Date
AbbVie USD 43.29B 3.9B Dec/2025
Alaunos Therapeutics USD 921K 153K Sep/2025
Amgen USD 25.49B 3.7B Dec/2025
Ardelyx USD 83.39M 1.67M Sep/2025
Arrowhead Research USD 347.42M 151.94M Dec/2025
Bayer EUR 28.96B 825M Sep/2025
Biogen USD 3.35B 59.4M Dec/2025
Corcept Therapeutics USD 172.26M 27.6M Sep/2025
Curis USD 19.37M 745K Jun/2025
Gilead Sciences USD 11.81B 485M Dec/2025
Infinity Pharmaceuticals USD 12.06M 775K Jun/2023
J&J USD 54.13B 3.26B Dec/2025
Karyopharm Therapeutics USD 87.16M 12.06M Sep/2025
Novartis USD 32B 286M Sep/2025
Novavax USD 429.87M 40.73M Sep/2025
PTC Therapeutics USD 968.43M 102.18M Dec/2025
Puma Biotechnology USD 82.73M 3.63M Sep/2025
Regeneron Pharmaceuticals USD 4.37B 56.7M Dec/2025
Roche Holding CHF 28B 421M Dec/2025
TG Therapeutics USD 156.81M 15.08M Sep/2025
Verastem USD 35.62M 4.65M Mar/2025
Vertex Pharmaceuticals USD 3.86B 614.1M Dec/2025